![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CELF1 |
Gene summary for CELF1 |
![]() |
Gene information | Species | Human | Gene symbol | CELF1 | Gene ID | 10658 |
Gene name | CUGBP Elav-like family member 1 | |
Gene Alias | BRUNOL2 | |
Cytomap | 11p11.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q92879 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10658 | CELF1 | Dong_P1 | Human | Prostate | Tumor | 6.45e-25 | 1.60e-01 | 0.035 |
10658 | CELF1 | Dong_P3 | Human | Prostate | Tumor | 5.46e-12 | 1.58e-01 | 0.0278 |
10658 | CELF1 | Dong_P4 | Human | Prostate | Tumor | 7.92e-07 | 1.09e-01 | 0.0292 |
10658 | CELF1 | Dong_P5 | Human | Prostate | Tumor | 1.27e-13 | -6.17e-02 | 0.053 |
10658 | CELF1 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 1.38e-02 | -2.89e-02 | 0.1531 |
10658 | CELF1 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.08e-07 | 1.19e-01 | 0.1545 |
10658 | CELF1 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 2.41e-05 | 1.77e-01 | 0.1569 |
10658 | CELF1 | P4_S8_cSCC | Human | Skin | cSCC | 5.98e-06 | 7.18e-02 | -0.3095 |
10658 | CELF1 | P5_S10_cSCC | Human | Skin | cSCC | 1.53e-02 | 1.20e-01 | -0.299 |
10658 | CELF1 | P1_cSCC | Human | Skin | cSCC | 3.42e-40 | 1.15e+00 | 0.0292 |
10658 | CELF1 | P2_cSCC | Human | Skin | cSCC | 5.26e-19 | 5.58e-01 | -0.024 |
10658 | CELF1 | P4_cSCC | Human | Skin | cSCC | 4.52e-11 | 4.45e-01 | -0.00290000000000005 |
10658 | CELF1 | P10_cSCC | Human | Skin | cSCC | 6.16e-26 | 7.64e-01 | 0.1017 |
10658 | CELF1 | cSCC_p7 | Human | Skin | cSCC | 3.90e-02 | 8.19e-02 | -0.2332 |
10658 | CELF1 | male-WTA | Human | Thyroid | PTC | 4.22e-48 | 2.83e-01 | 0.1037 |
10658 | CELF1 | PTC01 | Human | Thyroid | PTC | 2.08e-15 | 3.12e-01 | 0.1899 |
10658 | CELF1 | PTC03 | Human | Thyroid | PTC | 2.34e-10 | 4.20e-01 | 0.1784 |
10658 | CELF1 | PTC04 | Human | Thyroid | PTC | 6.07e-49 | 8.54e-01 | 0.1927 |
10658 | CELF1 | PTC05 | Human | Thyroid | PTC | 6.52e-29 | 1.05e+00 | 0.2065 |
10658 | CELF1 | PTC06 | Human | Thyroid | PTC | 6.13e-42 | 9.50e-01 | 0.2057 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
GO:003133110 | Cervix | CC | positive regulation of cellular catabolic process | 91/2311 | 427/18723 | 9.64e-08 | 5.25e-06 | 91 |
GO:004348410 | Cervix | CC | regulation of RNA splicing | 42/2311 | 148/18723 | 1.25e-07 | 6.24e-06 | 42 |
GO:00064029 | Cervix | CC | mRNA catabolic process | 56/2311 | 232/18723 | 4.81e-07 | 1.83e-05 | 56 |
GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
GO:00064019 | Cervix | CC | RNA catabolic process | 62/2311 | 278/18723 | 2.18e-06 | 6.56e-05 | 62 |
GO:000641710 | Cervix | CC | regulation of translation | 89/2311 | 468/18723 | 1.86e-05 | 3.46e-04 | 89 |
GO:002261310 | Cervix | CC | ribonucleoprotein complex biogenesis | 88/2311 | 463/18723 | 2.11e-05 | 3.82e-04 | 88 |
GO:004802410 | Cervix | CC | regulation of mRNA splicing, via spliceosome | 28/2311 | 101/18723 | 2.41e-05 | 4.19e-04 | 28 |
GO:002261810 | Cervix | CC | ribonucleoprotein complex assembly | 49/2311 | 220/18723 | 2.52e-05 | 4.29e-04 | 49 |
GO:00507273 | Cervix | CC | regulation of inflammatory response | 75/2311 | 386/18723 | 3.95e-05 | 6.18e-04 | 75 |
GO:007182610 | Cervix | CC | ribonucleoprotein complex subunit organization | 49/2311 | 227/18723 | 5.91e-05 | 8.54e-04 | 49 |
GO:00506849 | Cervix | CC | regulation of mRNA processing | 33/2311 | 137/18723 | 1.06e-04 | 1.35e-03 | 33 |
GO:00610139 | Cervix | CC | regulation of mRNA catabolic process | 38/2311 | 166/18723 | 1.07e-04 | 1.36e-03 | 38 |
GO:00459277 | Cervix | CC | positive regulation of growth | 53/2311 | 259/18723 | 1.33e-04 | 1.64e-03 | 53 |
GO:19033136 | Cervix | CC | positive regulation of mRNA metabolic process | 29/2311 | 118/18723 | 1.86e-04 | 2.18e-03 | 29 |
GO:00467008 | Cervix | CC | heterocycle catabolic process | 80/2311 | 445/18723 | 3.23e-04 | 3.42e-03 | 80 |
GO:00346559 | Cervix | CC | nucleobase-containing compound catabolic process | 74/2311 | 407/18723 | 3.77e-04 | 3.88e-03 | 74 |
GO:00434889 | Cervix | CC | regulation of mRNA stability | 35/2311 | 158/18723 | 3.80e-04 | 3.89e-03 | 35 |
GO:00611576 | Cervix | CC | mRNA destabilization | 22/2311 | 84/18723 | 4.18e-04 | 4.23e-03 | 22 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CELF1 | SNV | Missense_Mutation | novel | c.1075N>A | p.Gly359Ser | p.G359S | protein_coding | tolerated(0.28) | benign(0) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
CELF1 | SNV | Missense_Mutation | c.432N>C | p.Lys144Asn | p.K144N | protein_coding | deleterious(0) | probably_damaging(0.951) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
CELF1 | SNV | Missense_Mutation | novel | c.1475N>A | p.Gly492Asp | p.G492D | protein_coding | deleterious(0) | possibly_damaging(0.53) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
CELF1 | SNV | Missense_Mutation | rs746684771 | c.470C>T | p.Ser157Leu | p.S157L | protein_coding | deleterious(0.02) | benign(0.257) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
CELF1 | SNV | Missense_Mutation | c.976G>T | p.Gly326Trp | p.G326W | protein_coding | deleterious(0.03) | probably_damaging(0.977) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
CELF1 | SNV | Missense_Mutation | c.1058N>T | p.Thr353Met | p.T353M | protein_coding | tolerated(0.07) | possibly_damaging(0.458) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
CELF1 | SNV | Missense_Mutation | c.563N>T | p.Ala188Val | p.A188V | protein_coding | deleterious(0) | probably_damaging(0.922) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | ||
CELF1 | SNV | Missense_Mutation | c.509N>A | p.Pro170His | p.P170H | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
CELF1 | SNV | Missense_Mutation | novel | c.1414N>G | p.Phe472Val | p.F472V | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
CELF1 | SNV | Missense_Mutation | novel | c.952N>A | p.Leu318Ile | p.L318I | protein_coding | tolerated(0.35) | probably_damaging(0.953) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |